Everolimus (an mTOR inhibitor) and bevacizumab (a monoclonal antibody against VEGF) have been the main target therapies that have been reported for the treatment of aggressive pituitary adenomas/PitNEts [15]. This evidence concerns the gene MTOR and pituitary gland adenoma.